Skip to main content
OpenTrials
Completed

NCT Number: NCT00990288

The Use of FLOSEAL to Reduce Bleeding in Total Knee Replacement Surgery

The purpose of this study is to determine if the agent, Floseal, can decrease the amount of blood patients lose after total knee replacement (TKR) surgery. If this product can be found to have an effect on bleeding, it may potentially reduce the problems associated with bleeding after knee replacement surgery such as pain, stiffness, and the need to have a blood transfusion. The subject's overall participation will be over a period of 6 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Hospital for Special Surgery

New York, 10021, United States

About this study

This is a prospective double blind randomized clinical trial of patients requiring unilateral total knee arthroplasty. The patients will be randomized intra-operatively to receiving Floseal or no treatment.

Both the patient and the observers will be blinded to whether the subject received Floseal or no treatment. Only the operating surgeons will be aware of whether Floseal or no treatment was given.

As was performed in the pilot study, randomization of Floseal or no treatment will be performed using the sealed envelope technique. Randomization will occur at the time of surgery. The statistician is responsible for maintaining the randomization schedule and issuing the sealed envelopes. The inner envelope will contain whether Floseal or no treatment is to be given on a card which will be counter-signed by the surgeon at the time of surgery. The inner envelope will then be sealed, followed by sealing of the outer envelope. Following the procedure, the surgeon will then take the sealed and signed envelope to surgeon who will store and file it in a locked cabinet in his office. The patients study number will be on the outside surface of the envelopes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Single Knee replacement for arthritis of the knee

Exclusion criteria

  • No inflammatory arthritis (ie. Rheumatoid arthritis)
  • No allergies to cow meat (bovine allergies
  • No history of bleeding disorders

Treatment and study plan

Hemostatic Matrix

Drug

FloSeal will be administered following the cementing of all knee components. Prior to release of the tourniquet and after the cement has cured, it will be applied to cut, exposed bone ends as well as the intra-articular soft tissues by the use of a delivery syringe, Direct manual pressure with a gauze sponge will be applied following its application for 2 minutes, ensuring that it adheres to the bleeding bone surface.

Other names: "FloSeal", a thrombin and collagen based agent

Primary outcomes

  1. Change in Hemoglobin on Day 0 Compared to Preoperatively

    Time frame: preoperatively and on the day of surgery

  2. Change in Hemoglobin on Day 0 Compared to Preoperatively

    Time frame: preoperatively and day of surgery

  3. Change in Hemoglobin On Day 1 Compared to Preoperatively

    Time frame: preoperatively and one day after surgery

  4. Change in Hematocrit on Day 1 Compared to Preoperatively

    Time frame: preoperatively and 1 day after surgery

  5. Change in Hemoglobin on Day 2 Compared to Preoperatively

    Time frame: preoperatively and two days after surgery

  6. Change in Hematocrit on Day 2 Compared to Preoperatively

    Time frame: preoperatively and two days after surgery

  7. Drain Output

    Time frame: 24 hours postoperatively

  8. Autologous Amount of Transfusion

    Time frame: three days postoperatively

  9. Homologous Amount of Transfusion

    Time frame: three days postoperatively

Secondary outcomes

  1. Range of Motion on Day 3

    Time frame: 3days postoperatively

  2. Visual Analog Pain Scale on Day 3

    Time frame: 3 days postoperatively

    A VAS is a measurement instrument that tries to measure a characteristic or attitude that cannot easily be measured.

    The pain VAS scale measures pain intensity on a scale of 0 to 10, with 0=no pain. A higher score indicates greater pain intensity.

  3. Range of Motion at Six Weeks

    Time frame: 6 weeks postoperatively

  4. Visual Analog Pain Scale at 6 Weeks

    Time frame: 6 weeks postoperatively

    A VAS is a measurement instrument that tries to measure a characteristic or attitude that cannot easily be measured.

    The pain VAS scale measures pain intensity on a scale of 0 to 10, with 0=no pain. A higher score indicates greater pain intensity.

Sponsors and collaborators

Lead sponsor

Hospital for Special Surgery, New York

Other

Collaborators

  • Baxter Healthcare Corporation

Registry information

Official study title

The Role of a Topical Hemostatic Agent in Reducing Blood Loss in Unilateral Total Knee Arthroplasty

Important dates

Study start
2007
Primary completion
2010
Study completion
2010
First posted
Oct 6, 2009
Registry last updated
Dec 12, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.